Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France
Open Access
- 23 May 2024
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 8 (4) , 539-557
Abstract
Background and Objectives In France, meningococcal serogroup B (MenB) is the most common serogroup causing invasive meningococcal disease (IMD) in infants and young children. Our objective was to illustrate the impact of model choices on health outcomes and the cost-effectiveness of infant vaccination with the multicomponent meningococcal serogroup B vaccine (4CMenB) versus no vaccine in France. Methods A previously published dynamic transmission-based cost-effectiveness model was adapted for the French context using updated, French-specific demographic, epidemiological, and cost data. IMD incidence and long-term sequelae were derived through analysis of French healthcare and surveillance databases. A collective perspective over a 100-year time horizon was adopted, with a discount rate of 2.5%, reduced to 1.5% after the first 30 years. Deterministic and probabilistic sensitivity and scenario analyses were performed. Results In the base case analysis, infant vaccination with 4CMenB avoided 3101 MenB IMD cases in infants aged < 1 year (− 54%) and 6845 cases in all age groups (− 21%). The estimated incremental cost-effectiveness ratio was €316,272/quality-adjusted life-year (QALY) but was highly sensitive to the types of sequelae included, MenB incidence, vaccine effectiveness parameters, and consideration of life-expectancy in IMD survivors (range: €65,272/QALY to €493,218/QALY). Conclusions Using economic models compliant with French methodology guidelines, 4CMenB does not seem cost-effective; however, results are sensitive to model choices and 4CMenB immunization is an effective strategy to prevent MenB IMD cases and to improve quality of life and economic burden associated with MenB IMD treatment, especially with regard to long-term sequelae.Keywords
Funding Information
- GlaxoSmithKline Biologicals SA
This publication has 51 references indexed in Scilit:
- Meningococcal carriage by age: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2010
- Long‐Term Effects of Child Death on Parents' Health‐Related Quality of Life: A Dyadic AnalysisFamily Relations, 2010
- Epidemic meningitis, meningococcaemia, and Neisseria meningitidisThe Lancet, 2007
- Impact of psychiatric disorders on health-related quality of life: general population surveyThe British Journal of Psychiatry, 2007
- A review of vaccine research and development: Meningococcal disease☆Vaccine, 2006
- The EQ-5D and the Health Utilities Index for permanent sequelae after meningitisJournal of Clinical Epidemiology, 2002
- Complications of Meningococcal Disease in College StudentsClinical Infectious Diseases, 2001
- Utility values associated with blindness in an adult populationBritish Journal of Ophthalmology, 2001
- Parents' utilities for outcomes of occult bacteremia.2000
- Long-Term Psychosocial Adaptation of Children Who Survive Burns Involving 80% or Greater Total Body Surface AreaThe Journal of Trauma: Injury, Infection, and Critical Care, 1998